Nontuberculous Mycobacterial Infection Market Exhibits a Revenue CAGR of 5.4 percent and Expected to Reach US 19.9 Billion by 2031 Growth Plus Reports
PRTKDelisted Stock | USD 2.18 0.00 0.00% |
About 56% of Paratek Pharmaceuticals' investor base is looking to short. The analysis of current outlook of investing in Paratek Pharmaceuticals suggests that many traders are alarmed regarding Paratek Pharmaceuticals' prospects. Paratek Pharmaceuticals' investing sentiment shows overall attitude of investors towards Paratek Pharmaceuticals.
Paratek |
Newark, New Castle, USA, April 24, 2023 -- As per the report by Growth Plus Reports, the global nontuberculous mycobacterial infection market size is valued at US 12.4 billion in 2022 and is expected to reach US 19.9 billion in 2031, at a CAGR of 5.4 percent during the forecast period, 2023-2031 The global nontuberculous mycobacterial infection market was valued and expected to rise during the forecast period with a significant rise in revenue share. The nontuberculous mycobacteria a
Read at finance.yahoo.com
Paratek Pharmaceuticals Fundamental Analysis
We analyze Paratek Pharmaceuticals' financials across various querterly and yearly statements, indicators and fundamental ratios. We help investors to determine the real value of Paratek Pharmaceuticals using virtually all public information available. We use both quantitative as well as qualitative analysis to arrive at the intrinsic value of Paratek Pharmaceuticals based on its fundamental data. In general, a quantitative approach, as applied to this company, focuses on analyzing financial statements comparatively, whereas a qaualitative method uses data that is important to a company's growth but cannot be measured and presented in a numerical way.
Current Ratio
Current Ratio Comparative Analysis
Paratek Pharmaceuticals is currently under evaluation in current ratio category among its peers. Current Ratio is calculated by dividing the Current Assets of a company by its Current Liabilities. It measures whether or not a company has enough cash or liquid assets to pay its current liability over the next fiscal year. The ratio is regarded as a test of liquidity for a company.
Paratek Pharmaceuticals Potential Pair-trading
One of the popular trading techniques among algorithmic traders is to use market-neutral strategies where every trade hedges away some risk. Because there are two separate transactions required, even if one position performs unexpectedly, the other equity can make up some of the losses. Below are some of the equities that can be combined with Paratek Pharmaceuticals stock to make a market-neutral strategy. Peer analysis of Paratek Pharmaceuticals could also be used in its relative valuation, which is a method of valuing Paratek Pharmaceuticals by comparing valuation metrics with similar companies.
Peers
Paratek Pharmaceuticals Related Equities
LYRA | Lyra Therapeutics | 5.00 | ||||
LPTX | Leap Therapeutics | 4.43 | ||||
ADAP | Adaptimmune Therapeutics | 3.23 | ||||
CRVS | Corvus Pharmaceuticals | 1.12 | ||||
JSPR | Jasper Therapeutics | 0.40 | ||||
IMMP | Immutep | 2.75 | ||||
AFMD | Affimed NV | 2.93 | ||||
EQ | Equillium | 4.11 | ||||
APTO | Aptose Biosciences | 5.26 | ||||
HOOK | Hookipa Pharma | 7.88 |
Check out Your Equity Center to better understand how to build diversified portfolios. Also, note that the market value of any company could be closely tied with the direction of predictive economic indicators such as signals in estimate. You can also try the Financial Widgets module to easily integrated Macroaxis content with over 30 different plug-and-play financial widgets.
Other Consideration for investing in Paratek Stock
If you are still planning to invest in Paratek Pharmaceuticals check if it may still be traded through OTC markets such as Pink Sheets or OTC Bulletin Board. You may also purchase it directly from the company, but this is not always possible and may require contacting the company directly. Please note that delisted stocks are often considered to be more risky investments, as they are no longer subject to the same regulatory and reporting requirements as listed stocks. Therefore, it is essential to carefully research the Paratek Pharmaceuticals' history and understand the potential risks before investing.
Portfolio Analyzer Portfolio analysis module that provides access to portfolio diagnostics and optimization engine | |
AI Portfolio Architect Use AI to generate optimal portfolios and find profitable investment opportunities | |
Share Portfolio Track or share privately all of your investments from the convenience of any device | |
Portfolio Comparator Compare the composition, asset allocations and performance of any two portfolios in your account | |
Correlation Analysis Reduce portfolio risk simply by holding instruments which are not perfectly correlated | |
Portfolio Dashboard Portfolio dashboard that provides centralized access to all your investments | |
Balance Of Power Check stock momentum by analyzing Balance Of Power indicator and other technical ratios | |
Financial Widgets Easily integrated Macroaxis content with over 30 different plug-and-play financial widgets | |
Stock Tickers Use high-impact, comprehensive, and customizable stock tickers that can be easily integrated to any websites |